



## Tarsus to Report Fourth Quarter and Full-Year 2024 Financial Results on Tuesday, February 25, 2025

February 20, 2025

IRVINE, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 5:00 a.m. PT / 8:00 a.m. ET on Tuesday, February 25, 2025, to report its fourth quarter and full-year 2024 financial results and provide a corporate update.

Participants may access the webcast [here](#). A recorded version of the call will be available on the website shortly after the completion of the webcast and will be archived there for approximately 90 days.

### **About Tarsus Pharmaceuticals, Inc.**

Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care and infectious disease prevention. XDEMZY<sup>®</sup> (lotilaner ophthalmic solution, 0.25%) is FDA approved in the United States for the treatment of *Demodex* blepharitis. Tarsus is also developing TP-04 for the potential treatment of Ocular Rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease.

### **Media Contact:**

Adrienne Kemp  
Sr. Director, Corporate Communications  
(949) 922-0801  
[AKemp@tarsusrx.com](mailto:AKemp@tarsusrx.com)

### **Investor Contact:**

David Nakasone  
Head of Investor Relations  
(949) 620-3223  
[DNakasone@tarsusrx.com](mailto:DNakasone@tarsusrx.com)